The Journal of infectious diseases · 2012
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.
СтатьяResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lederman Edith R, Davidson Whitni, Groff Harold L, Smith Scott K, Warkentien Tyler, Li Yu, Wilkins Kimberly A, Karem Kevin L, Akondy Rama S, Ahmed Rafi, Frace Michael, Shieh Wun-Ju, Zaki Sherif, Hruby Dennis E, Painter Wendy P, Bergman Kimberly L, Cohen Jeffrey I, Damon Inger K
Аннотация
Progressive vaccinia (PV) is a rare but potentially lethal complication that develops in smallpox vaccine recipients with severely impaired cellular immunity. We describe a patient with PV who required treatment with vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001. We describe the various molecular, pharmacokinetic, and immunologic studies that provided guidance to escalate and then successfully discontinue therapy. Despite development of resistance to ST-246 during treatment, the patient had resolution of PV. This case demonstrates the need for continued development of novel anti-orthopoxvirus pharmaceuticals and the importance of both intensive and timely clinical and laboratory support in management of PV.